Art. 2 Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…

Criteria for designation

In forcesince 19 Jun 2018cited 4×
1.

Prevalence of a condition in the Community

For the purpose of establishing, pursuant to the first subparagraph of Article 3(1)(a) of Regulation (EC) No 141/2000, that a medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10000 persons in the Community, the following specific rules shall apply and the documentation listed below shall be provided in accordance with the guidance drawn up pursuant to Article 5(3) of Regulation (EC) No 141/2000:

(a)

the documentation shall include appended authoritative references which demonstrate that the disease or conditions for which the medicinal product would be administered, affects not more than five in 10000 persons in the Community at the time at which the application for designation is submitted, where these are available;

(b)

the data shall include appropriate details on the condition intended to be treated and a justification of the life-threatening or chronically debilitating nature of the condition supported by scientific or medical references;

(c)

the documentation submitted by the sponsor shall include or refer to a review of the relevant scientific literature, and shall provide information from relevant databases in the Community, where these are available. Where no database in the Community is available, reference may be made to databases available in third countries, provided the appropriate extrapolations are made;

(d)

where a disease or condition has been considered within the framework of other Community activities on rare diseases, this information shall be provided. In the case of diseases or conditions included in projects financially supported by the Community in order to improve information on rare diseases, a relevant extract from this information, including in particular, details of the prevalence of the disease or condition in question, shall be provided.

2.

Potential for return on investment

For the purpose of establishing, pursuant to the second subparagraph of Article 3(1)(a) of Regulation (EC) No 141/2000, that a medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community, and that without incentives it is unlikely that the marketing of the medicinal product in the Community would generate sufficient return to justify the necesary investment, the following specific rules shall apply and the appropriate documentation shall be provided in accordance with the guidance drawn up pursuant to Article 5(3) of Regulation (EC) No 141/2000:

(a)

the data shall include appropriate details on the condition intended to be treated and a justification of the life-threatening or seriously debilitating or serious and chronic nature of the condition supported by scientific or medical references;

(b)

the documentation submitted by the sponsor shall include data on all costs that the sponsor has incurred in the course of developing the medicinal product;

(c)

the documentation provided shall include details of any grants, tax incentives or other cost recovery provisions received either within the Community or in third countries;

(d)

in cases where the medicinal product is already authorised for any indication or where the medicinal product is under investigation for one or more other indications, a clear explanation of and justification for the method that is used to apportion the development costs among the various indications shall be provided;

(e)

a statement of and justification for all development costs that the sponsor expects to incur after the submission of the application for designation shall be provided;

(f)

a statement of and justification for all production and marketing costs that the sponsor has incurred in the past and expects to incur during the first 10 years that the medicinal product is authorised shall be provided;

(g)

an estimate and justification for the expected revenues from sales of the medicinal product in the Community during the first 10 years after authorisation;

(h)

all cost and revenue data shall be determined in accordance with generally accepted accounting practices and shall be certified by a registered accountant in the Community;

(i)

the documentation provided shall include information on the prevalence and incidence in the Community of the condition for which the medicinal product would be administered at the time at which the application for designation is submitted.

3.

Existence of other methods of diagnosis, prevention or treatment

An application for designation of a medicinal product as an orphan medicinal product may be submitted in accordance with either paragraph 1 or paragraph 2 of this Article. Irrespective of whether an application for designation is submitted in accordance with paragraph 1 or 2, the sponsor must additionally establish that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question, or if such method exists that the medicinal product will be of significant benefit to those affected by that condition.

For the purpose of establishing, pursuant to Article 3(1)(b) of Regulation (EC) No 141/2000 that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question, or if such method exists that the medicinal product will be of significant benefit to those affected by that condition, the following rules shall apply:

(a)

details of any existing diagnosis, prevention or treatment methods of the condition in question that have been authorised in the Community shall be provided, making reference to scientific and medical literature or other relevant information. These may include authorised medicinal products, medical devices or other methods of diagnosis, prevention or treatment which are used in the Community;

(b)

either a justification as to why the methods referred to in paragraph (a) are not considered satisfactory;

or

(c)

a justification for the assumption that the medicinal product for which designation is sought will be of significant benefit to those affected by the condition.

4.

General provisions

(a)

A sponsor applying for designation of a medicinal product as an orphan medicinal product shall apply for designation at any stage of the development of the medicinal product before the application for marketing authorisation is made. An application for designation may however be submitted for a new therapeutic indication for an already authorised medicinal product. In this case, the marketing authorisation holder shall apply for a separate marketing authorisation which will cover only the orphan indication(s).

(b)

More than one sponsor may obtain designation as an orphan medicinal product for the same medicinal product intended to prevent, treat or diagnose the same disease or condition, provided that a complete application for designation as laid down by the guidelines specified in Article 5(3) is submitted in each case.

(c)

Where a medicinal product is designated by the Committee for Orphan Medicinal Products reference to the criteria for designation will be made either to Article 2(1) or to Article 2(2) of this Regulation.

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    Sixthly, the Court rejects the applicant’s argument that, even if it improved human fibrinogen, it would be able to obtain the status of orphan medicinal product for that improved medicinal product only if the application for designation …

    9 Sep 2010 · 62007TJ0264

  • BSG, Urteil vom 3. Juli 2012 - B 1 KR 25/11 RDecision

    3 Jul 2012 · KSRE133301518

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    According to Article 2(3), second subparagraph, heading (a), of Regulation No 847/2000, ‘[satisfactory methods] may include authorised medicinal products, medical devices or other methods of diagnosis, prevention or treatment which are …

    23 Sep 2020 · 62019TJ0549

  • Judgment of the General Court (Seventh Chamber) of 22 March 2018. Shire Pharmaceuticals Ireland Ltd v European Medicines Agency.Decision

    The EMA and the Commission further state that, referring to Article 2(4)(b) of Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as …

    22 Mar 2018 · 62016TJ0080